Circulating hsa-miR-622 Biomarker for HGSOC Treatment Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic and prognostic tools for high-grade serous ovarian carcinoma (HGSOC) are inadequate, particularly in predicting response to chemotherapy and detecting recurrence, leading to poor survival rates and ineffective treatments.
Innovation Solution
The use of circulating miRNA hsa-miR-622 as a biomarker for predicting patient response to platinum-based chemotherapy and PARP inhibitors, determined through RT-qPCR in biofluids such as blood, serum, or plasma, allowing for personalized treatment strategies and early detection of recurrence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional diagnostic tools and surgery are used for HGSOC diagnosis and prognosis, then definitive diagnosis can be obtained, but the process is invasive and cannot predict recurrence or treatment response early enough
Solution Approach 1:
The patent extracts and measures circulating miRNA molecules from blood plasma as a non-invasive diagnostic approach. Specifically, miR-622 and other miRNAs are detected in plasma samples to predict ovarian cancer recurrence and treatment response, eliminating the need for invasive surgical procedures for diagnostic purposes
Solution Approach 2:
The patent uses circulating miRNA molecules as intermediary biomarkers that mediate between the tumor and the diagnostic test. These miRNAs serve as surrogate indicators of tumor presence and characteristics, allowing indirect but accurate diagnosis and prognosis without direct tissue sampling
2Reliability
If current prognostic methods are used, then treatment decisions can be made, but response to chemotherapy and risk of recurrence cannot be predicted accurately
Solution Approach 1:
The patent implements a feedback mechanism by measuring miRNA levels before treatment and monitoring changes during and after treatment. The baseline miR-622 level provides feedback on likely treatment response, and subsequent changes in miRNA levels provide feedback on treatment effectiveness and early recurrence detection
Solution Approach 2:
The patent performs preliminary assessment of miRNA expression levels before initiating chemotherapy to predict treatment response. This preliminary action allows clinicians to anticipate which patients will respond to platinum-based chemotherapy and adjust treatment plans accordingly, rather than waiting for treatment outcomes to become apparent
3Loss of time
If surgery and staging are performed to determine prognosis, then treatment planning can be guided, but early recurrence detection is delayed until clinical symptoms appear
Solution Approach 1:
The patent establishes continuous monitoring of miRNA levels in plasma at regular intervals after treatment. This continuous surveillance detects molecular signs of recurrence before clinical symptoms or radiographic evidence appear, extending the detection window and enabling earlier intervention
Solution Approach 2:
The patent replaces complex imaging and repeated surgical staging procedures with a simple blood test that measures miRNA levels. This substitution maintains high prognostic accuracy while reducing the complexity and invasiveness of the monitoring system
Data Source
Figure 1~2
Figure 3
Figure 4A~4D
AI summary
The present invention relates to the identification of a biomarker, consisting in a circulating miRNA, suitable for use in the diagnosis and prognosis of high-grade serous ovarian carcinoma (HGSOC), and to diagnostic kits for use in such diagnosis.